Homology Medicines, Inc. (FIXX) Analysts See $-0.34 EPS

July 14, 2018 - By Christine McCrea

Analysts expect Homology Medicines, Inc. (NASDAQ:FIXX) to report $-0.34 EPS on August, 13.After having $-4.21 EPS previously, Homology Medicines, Inc.’s analysts see -91.92 % EPS growth. The stock increased 0.09% or $0.02 during the last trading session, reaching $21.76. About 58,547 shares traded. Homology Medicines, Inc. (NASDAQ:FIXX) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The company has market cap of $809.22 million. The Company’s proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. It currently has negative earnings. The company's various set of AAVHSCs allows firm to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities?gene editing and gene therapy.

Homology Medicines, Inc. (NASDAQ:FIXX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: